(CAH) Cardinal Health - Overview
Stock: Pharmaceuticals, Medical, Surgical, Laboratory, Kits
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.25% |
| Yield on Cost 5y | 4.35% |
| Yield CAGR 5y | 0.94% |
| Payout Consistency | 93.5% |
| Payout Ratio | 29.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 51.6% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.04 |
| Alpha | 76.56 |
| Character TTM | |
|---|---|
| Beta | 0.317 |
| Beta Downside | 0.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.14% |
| CAGR/Max DD | 2.52 |
Description: CAH Cardinal Health January 28, 2026
Cardinal Health, Inc. (NYSE:CAH) is a U.S.–based, globally operating healthcare services and products firm that segments its operations into Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution. It supplies hospitals, health systems, pharmacies, ambulatory surgery centers, labs, physician offices, and home-care patients with branded and generic drugs, specialty pharmaceuticals, over-the-counter items, and a broad portfolio of medical-surgical devices, including gloves, needles, kits, and radiopharmaceuticals, while also offering supply-chain and pharmacy-management services.
In its most recent fiscal year (2025), Cardinal Health reported total revenue of $184.2 billion, a 3.1% year-over-year increase driven primarily by growth in specialty drug distribution (+5.4%) and a modest rebound in medical-surgical product sales (+2.0%). Adjusted EBITDA margin expanded to 5.6% from 4.9% in 2024, reflecting cost-containment initiatives and higher pricing power in specialty contracts. Free cash flow reached $2.9 billion, supporting a $1.2 billion share-repurchase program and a $750 million dividend increase.
Key sector drivers affecting Cardinal Health include the continued aging of the U.S. population, which is projected to lift overall healthcare spending by ~4% CAGR through 2030, and ongoing drug-pricing reforms that pressure margins on generic pharmaceuticals but create opportunities in specialty and biosimilar distribution. Additionally, supply-chain digitization and demand for integrated logistics solutions remain strong, with the healthcare distribution market expected to grow ~6% annually, favoring firms with advanced technology platforms.
For a deeper, data-rich assessment of how these trends translate into valuation levers, consider exploring the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 1.59b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.57 > 1.0 |
| NWC/Revenue: -0.74% < 20% (prev -0.79%; Δ 0.05% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.02b > Net Income 1.59b |
| Net Debt (4.44b) to EBITDA (3.26b): 1.36 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (239.0m) vs 12m ago -2.45% < -2% |
| Gross Margin: 3.66% > 18% (prev 0.03%; Δ 363.0% > 0.5%) |
| Asset Turnover: 476.8% > 50% (prev 520.9%; Δ -44.11% > 0%) |
| Interest Coverage Ratio: 9.21 > 6 (EBITDA TTM 3.26b / Interest Expense TTM 263.0m) |
Altman Z'' 0.26
| A: -0.03 (Total Current Assets 38.54b - Total Current Liabilities 40.27b) / Total Assets 55.23b |
| B: 0.02 (Retained Earnings 1.12b / Total Assets 55.23b) |
| C: 0.05 (EBIT TTM 2.42b / Avg Total Assets 49.14b) |
| D: 0.06 (Book Value of Equity 3.70b / Total Liabilities 57.96b) |
| Altman-Z'' Score: 0.26 = B |
Beneish M -2.79
| DSRI: 1.12 (Receivables 13.77b/11.78b, Revenue 234.31b/224.29b) |
| GMI: 0.92 (GM 3.66% / 3.36%) |
| AQI: 1.42 (AQ_t 0.25 / AQ_t-1 0.18) |
| SGI: 1.04 (Revenue 234.31b / 224.29b) |
| TATA: -0.06 (NI 1.59b - CFO 5.02b) / TA 55.23b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of CAH shares?
Over the past week, the price has changed by +7.55%, over one month by +10.58%, over three months by +15.73% and over the past year by +80.49%.
Is CAH a buy, sell or hold?
- StrongBuy: 9
- Buy: 2
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CAH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 234.2 | 3.1% |
| Analysts Target Price | 234.2 | 3.1% |
| ValueRay Target Price | 341.2 | 50.2% |
CAH Fundamental Data Overview February 02, 2026
P/E Forward = 21.692
P/S = 0.2179
P/B = 16.0657
P/EG = 2.008
Revenue TTM = 234.31b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 8.98b USD (from longTermDebt, last quarter)
Short Term Debt = 52.0m USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.44b USD (from netDebt column, last quarter)
Enterprise Value = 55.49b USD (51.05b + Debt 9.03b - CCE 4.59b)
Interest Coverage Ratio = 9.21 (Ebit TTM 2.42b / Interest Expense TTM 263.0m)
EV/FCF = 12.46x (Enterprise Value 55.49b / FCF TTM 4.45b)
FCF Yield = 8.02% (FCF TTM 4.45b / Enterprise Value 55.49b)
FCF Margin = 1.90% (FCF TTM 4.45b / Revenue TTM 234.31b)
Net Margin = 0.68% (Net Income TTM 1.59b / Revenue TTM 234.31b)
Gross Margin = 3.66% ((Revenue TTM 234.31b - Cost of Revenue TTM 225.72b) / Revenue TTM)
Gross Margin QoQ = 3.62% (prev 3.66%)
Tobins Q-Ratio = 1.00 (Enterprise Value 55.49b / Total Assets 55.23b)
Interest Expense / Debt = 0.89% (Interest Expense 80.0m / Debt 9.03b)
Taxrate = 24.08% (144.0m / 598.0m)
NOPAT = 1.84b (EBIT 2.42b * (1 - 24.08%))
Current Ratio = 0.96 (Total Current Assets 38.54b / Total Current Liabilities 40.27b)
Debt / Equity = -3.14 (negative equity) (Debt 9.03b / totalStockholderEquity, last quarter -2.88b)
Debt / EBITDA = 1.36 (Net Debt 4.44b / EBITDA 3.26b)
Debt / FCF = 1.00 (Net Debt 4.44b / FCF TTM 4.45b)
Total Stockholder Equity = -2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.25% (Net Income 1.59b / Total Assets 55.23b)
RoE = -55.00% (negative equity) (Net Income TTM 1.59b / Total Stockholder Equity -2.90b)
RoCE = 39.82% (EBIT 2.42b / Capital Employed (Equity -2.90b + L.T.Debt 8.98b))
RoIC = 34.61% (NOPAT 1.84b / Invested Capital 5.31b)
WACC = 6.12% (E(51.05b)/V(60.09b) * Re(7.08%) + D(9.03b)/V(60.09b) * Rd(0.89%) * (1-Tc(0.24)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.43%
[DCF Debug] Terminal Value 85.78% ; FCFF base≈3.10b ; Y1≈3.21b ; Y5≈3.63b
Fair Price DCF = 404.4 (EV 100.52b - Net Debt 4.44b = Equity 96.08b / Shares 237.6m; r=6.12% [WACC]; 5y FCF grow 3.48% → 2.90% )
EPS Correlation: 6.49 | EPS CAGR: -44.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.69 | Revenue CAGR: 9.56% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.75 | Chg30d=+0.056 | Revisions Net=+4 | Analysts=11
EPS current Year (2026-06-30): EPS=10.02 | Chg30d=+0.189 | Revisions Net=+7 | Growth EPS=+21.6% | Growth Revenue=+16.5%
EPS next Year (2027-06-30): EPS=11.29 | Chg30d=+0.207 | Revisions Net=+8 | Growth EPS=+12.7% | Growth Revenue=+8.6%